Description
Springer Monoclonal Gammopathies and the Kidney 1st Editon 2010 Softbound by G. Touchard, Dr Aucouturier, O. Hermine, Pierre Ronco
I: The Culprits: the Plasma Cell Dyscrasias.- 1 Physiopathology of malignant B cell lymphoproliferations.- 2 Immunoglobulin synthesis and secretion.- 3 Immunoglobulin decreased solubility diseases: pathologies of the V domains?.- 4 Megalin, cubilin and immunoglobulin light chains: receptor-mediated uptake of light chains in kidney proximal tubule.- II: The Victim: the Tubule.- 5 Pathophysiology of myeloma kidney.- 6 Myeloma cast nephropathy: clinical presentation.- 7 New therapeutic approaches for the myeloma patient with and without renal failure.- 8 Adult Fanconi’s syndrome due to monoclonal immunoglobulin light chains: an underdiagnosed disease with unexpected clinical and pathologic heterogeneity.- 9 Monoclonal immunoglobulin light chains associated to Fanconi’s syndrome.- III: The Victim: the Glomerulus.- 10 Ultrastructural pattern and classification of renal monoclonal immunoglobulin deposits.- 11 Morphological aspects in light chain deposition disease.- 12 Renal monoclonal immunoglobulin deposition disease (MIDD): the Columbia experience.- 13 Monoclonal cryoglobulinemia kidney.- 14 Fibrillary glomerulonephritis: defining the disease spectrum.- 15 Glomerulonephritis with organized immunoglobulin deposits: fibrillar and microtubular deposits are associated with distinct immunological features.- IV: Immunoglobulins Amyloidosis.- 16 Clinical features and management of amyloidosis.- 17 Fibrillogenesis and therapy of amyloidosis: an equilibrium approach.- 18 Immunoglobulin light chain amyloidosis and the kidney.- 19 Treating primary systemic amyloidosis with stem cell transplantation: outcomes in renal amyloidosis.- 20 Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients.- 21 Presentation of the French multicentre randomized trial comparing intensive and conventional treatment for AL amyloidosis.- 22 Amyloidosis: Round Table.- Oral communications.- Poster communications.